Herranz Raquel, Oto Julia, Plana Emma, Fernández-Pardo Álvaro, Cana Fernando, Martínez-Sarmiento Manuel, Vera-Donoso César D, España Francisco, Medina Pilar
Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain.
Angiology and Vascular Surgery Service, La Fe University and Polytechnic Hospital, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain.
Cancers (Basel). 2021 Mar 22;13(6):1448. doi: 10.3390/cancers13061448.
Bladder cancer (BC) is among the most frequent cancer types in the world and is the most lethal urological malignancy. Presently, diagnostic and follow-up methods for BC are expensive and invasive. Thus, the identification of novel predictive biomarkers for diagnosis, progression, and prognosis of BC is of paramount importance. To date, several studies have evidenced that cell-free DNA (cfDNA) found in liquid biopsies such as blood and urine may play a role in the particular scenario of urologic tumors, and its analysis may improve BC diagnosis report about cancer progression or even evaluate the effectiveness of a specific treatment or anticipate whether a treatment would be useful for a specific patient depending on the tumor characteristics. In the present review, we have summarized the up-to-date studies evaluating the value of cfDNA as potential diagnostic, prognostic, or monitoring biomarker for BC in several biofluids.
膀胱癌（BC）是全球最常见的癌症类型之一，也是最致命的泌尿系统恶性肿瘤。目前，膀胱癌的诊断和随访方法昂贵且具有侵入性。因此，识别用于膀胱癌诊断、进展和预后的新型预测生物标志物至关重要。迄今为止，多项研究已证明，在血液和尿液等液体活检中发现的游离DNA（cfDNA）可能在泌尿系统肿瘤的特定情况下发挥作用，其分析可能改善膀胱癌关于癌症进展的诊断报告，甚至评估特定治疗的有效性，或根据肿瘤特征预测一种治疗方法对特定患者是否有用。在本综述中，我们总结了最新研究，评估了cfDNA作为几种生物流体中膀胱癌潜在诊断、预后或监测生物标志物的价值。
